Announcements
- Teleflex Publishes 2023 Global Impact Report
- Teleflex Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray
- Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH
- Teleflex Announces Quarterly Dividend
- Teleflex Reports First Quarter Financial Results and Full Year 2024 Outlook
- Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
- Teleflex Announces the Limited Market Release of the Wattson™ Temporary Pacing Guidewire
- Teleflex to Present at the BofA Securities 2024 Health Care Conference
- Teleflex Announces First Quarter 2024 Earnings Conference Call Information
- Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 47.10m |
Free float | 46.98m |
P/E (TTM) | 33.42 |
Market cap | 9.85bn USD |
EPS (TTM) | 6.26 USD |
Annual div (ADY) | 1.23 CHF |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | May 14 2024 |
Div pay-date | Jun 14 2024 |
Data delayed at least 15 minutes.
More ▼